首页> 外国专利> Compound, isomers to be enantiomerically pure thereof, pharmaceutical composition and methods of inhibiting pde4 and mmp, modulating tnf-alpha production, treating or preventing mds, treating myeloproliferative disease, unwanted angiogenesis, cancer, a disease, lung inflammation , depression, chronic obstructive pulmonary disorder, inflammatory bowel disease, atopic dermatitis, psoriasis, crohn's disease, rheumatoid arthritis, asthma, multiple sclerosis and heart disease in a mammal and to treat, prevent or control complex regional pain syndrome

Compound, isomers to be enantiomerically pure thereof, pharmaceutical composition and methods of inhibiting pde4 and mmp, modulating tnf-alpha production, treating or preventing mds, treating myeloproliferative disease, unwanted angiogenesis, cancer, a disease, lung inflammation , depression, chronic obstructive pulmonary disorder, inflammatory bowel disease, atopic dermatitis, psoriasis, crohn's disease, rheumatoid arthritis, asthma, multiple sclerosis and heart disease in a mammal and to treat, prevent or control complex regional pain syndrome

机译:化合物,其对映体纯的异构体,抑制pde4和mmp,调节tnf-α产生,治疗或预防mds,治疗骨髓增生性疾病,不良血管生成,癌症,疾病,肺部炎症,抑郁症,慢性阻塞性肺的药物组合物和方法哺乳动物的疾病,炎症性肠病,特应性皮炎,牛皮癣,克罗恩病,类风湿性关节炎,哮喘,多发性硬化症和心脏病,以治疗,预防或控制复杂的局部疼痛综合征

摘要

"COMPOUND, WE ARE EMERGIALLY PURE OF THE SAME, PHARMACEUTICAL COMPOSITION AND METHODS OF INHIBITING PDE4 AND MMP, MODULATING TNF-ALPHA PRODUCTION, TREATING OR PREDICTING MDS, TREATING MYELOPROGENE DISEASE, INFLUENCE OF THE DISEASE, MYELOPROGEN DISEASE, LUNGS, DEPRESSION, CHRONIC OBSTRUCTIVE PULMONARY DISORDER, INFLAMMATORY DISEASE OF THE INTESTIN, ATOPIC DERMATITIS, PSORIASIS, CROHN'S DISEASE, ASTHMA, COMPULAR DIFFERENAL ELL REGULAR AND AXIAL DIFFERENAL CONTROL . The invention encompasses new pharmaceutically acceptable compounds, salts, hydrates, solvates, solvates, clathrates, enantiomers, diastereomers, racemates or mixtures of stereoisomers thereof, pharmaceutical compositions of these compounds and methods of use of these compounds in mammals for the treatment or prevention of diseases associated with PDE4.
机译:“化合物,我们在纯度上完全抑制PDE4和MMP,调节TNF-α的产生,治疗或预测MDS,治疗肌原性疾病,疾病的影响,疾病,结节,病原性变质,肠道疾病,肠道炎症,原子性皮肤炎,牛皮癣,克罗恩氏病,哮喘,常规微分细胞控制和轴向微分控制。本发明包括新的药学上可接受的化合物,盐,水合物,反式,溶剂化物,溶剂化物,溶剂化物消旋体或其立体异构体的混合物,这些化合物的药物组合物以及这些化合物在哺乳动物中用于治疗或预防与PDE4相关的疾病的使用方法。

著录项

  • 公开/公告号BR0317885A

    专利类型

  • 公开/公告日2005-12-06

    原文格式PDF

  • 申请/专利权人 CELGENE CORPORATION;

    申请/专利号BR20030317885

  • 申请日2003-12-29

  • 分类号C07D209/44;A61K31/4035;

  • 国家 BR

  • 入库时间 2022-08-21 21:40:25

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号